Biocryst Pharmaceuticals (BCRX) Interest & Investment Income (2010 - 2026)

Biocryst Pharmaceuticals has reported Interest & Investment Income for 17 years, with the latest figure at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 25.4% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $9.9 million (down 27.94% YoY), and the FY2025 full-year result was $10.7 million, down 27.65% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.3 million, down from $2.9 million in the prior quarter.
• The five-year high for Interest & Investment Income was $4.5 million in Q4 2023, with the low at $54000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $2.9 million across 5 years, with a median of $3.0 million in 2025.
• Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 19455.56% — and 2025, when it slumped 37.68%.
• Biocryst Pharmaceuticals' Interest & Investment Income stood at $2.7 million in 2022, then surged by 65.13% to $4.5 million in 2023, then fell by 20.04% to $3.6 million in 2024, then slipped by 19.05% to $2.9 million in 2025, then decreased by 21.94% to $2.3 million in 2026.
• The last three Interest & Investment Income figures came in at $2.3 million (Q1 2026), $2.9 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.